| Company/Division name | Eurofins Genomics US |
| Parent company | Eurofins Genomics |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2024 |
| Year reshoring implemented or to be implemented: | 2025 |
| Country(ies) from which reshored: | Luxembourg |
| City reshored to: | Louisville |
| State(s) reshored to: | KY |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Life Science Products |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Higher productivity, Lead time/Time to market, Proximity to customers/market |
